You are here » Home » Companies » Company Overview » Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd.

BSE: 506820 Sector: Health care
NSE: ASTRAZEN ISIN Code: INE203A01020
BSE LIVE 15:45 | 09 Dec 947.45 9.80
(1.05%)
OPEN

950.00

HIGH

954.00

LOW

945.60

NSE LIVE 15:31 | 09 Dec 953.55 15.65
(1.67%)
OPEN

945.00

HIGH

955.90

LOW

942.15

OPEN 950.00
PREVIOUS CLOSE 937.65
VOLUME 191
52-Week high 1348.00
52-Week low 916.00
P/E 115.12
Mkt Cap.(Rs cr) 2368.62
Buy Price 0.00
Buy Qty 0.00
Sell Price 947.45
Sell Qty 4.00
OPEN 950.00
CLOSE 937.65
VOLUME 191
52-Week high 1348.00
52-Week low 916.00
P/E 115.12
Mkt Cap.(Rs cr) 2368.62
Buy Price 0.00
Buy Qty 0.00
Sell Price 947.45
Sell Qty 4.00

Astrazeneca Pharma India Ltd. (ASTRAZEN) - Company History

Astrazeneca Pharma India formerly known as Astra-IDL (AIL), a joint venture of Astra Zeneca, UK and Hinduja controlled IDL is a market leader in local anesthetics with xylocaine. The, UB's 100% subsidiary, UB Biotek, has tied up with the Company to market its newly-patented anti-obesity nutraceutical. The herbal product, Hydroxycitrisol, extracted from garcinia (kokum), is one of two UB technologies to recently get US patents. It is due to complete clinical tests at AIL and may hit the market by this year-end. AIL is also due to get ayurvedic clearances from the Union Department of Indian Systems of Medicine while the US FDA approval is also pending. The revenue expenditure incurred during the financial year 1999-2000 and 2000-2001 on ERP implementation and US FDA certification is being treated as deferred revenue expenditure in the books of accounts of the the company. The ERP expenditure is being charged off in 3 equal annual instalments from the year in which it is incurred. The US FDA certification expenses will be amortised over a period of 3 years from the year in which such certification is obtained. The company has expanded the installed capacity of Injectables during the year 2001 by 0.20 crores(Nos) and with this expansion the total capacity has been increased to 2.40 crores(Nos). Astra Pharmaceuticals AB, Sweden recently acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden ( now known as AstraZeneca AB, Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. The Company's marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commissioned the automatic ampoule filling machine and thereby increased the capacity of the same from 10 Mio to 12 Mio. The company has launched during the year 2003,an Oncology product,Arimidex,for the management of breast cancer. The Pharmaceutical major Astrazeneca has decided to make its Astrazeneca India's R&D as a part of its global R&D organisation.The company has decided to expand its process R&D group in Bangalore.It has purchased 14200 Sq Mtr of land,which is a part of its "Avishkar" campus,where it has set up R&D centre.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard